GTCR Announces Second Partnership with Ed Fiorentino to Form Crealta Pharmaceuticals

  GTCR Announces Second Partnership with Ed Fiorentino to Form Crealta
  Pharmaceuticals

Business Wire

CHICAGO -- August 6, 2013

GTCR, a leading private equity firm, today announced that it has entered into
a partnership with Ed Fiorentino to form Crealta Pharmaceuticals, Inc.
(“Crealta”). The new company, headquartered in Lake Forest, Illinois, will
focus on acquiring specialty pharmaceutical companies and products as part of
a strategy to build a leading company in the industry. Target acquisition
opportunities include products which are already approved or currently
marketed, as well as late-stage development assets. GTCR may invest up to $200
million of equity capital to support management's strategy. Mr. Fiorentino
will serve as Chairman and Chief Executive Officer of Crealta.

Crealta is the second partnership between GTCR and Ed Fiorentino. Previously,
Mr. Fiorentino was Chief Executive Officer of Actient Pharmaceuticals, a
specialty pharmaceutical company which was acquired in April 2013 by Auxilium
Pharmaceuticals (NASDAQ: AUXL). Actient was established in March 2009 in
partnership with GTCR. Through a series of five proprietary acquisitions,
Actient built a diversified portfolio of commercial products and pipeline
programs and created a unique specialty pharmaceutical company focused on the
treatment of urological conditions.

Prior to his role building Actient, Ed was a former corporate officer and
22-year veteran of Abbott Laboratories (NYSE:ABT). His senior-level management
experience at Abbott includes Corporate Vice President of Pharmaceutical
Commercial Operations, where he was responsible for all U.S. sales, marketing
and new product planning. He also served as Senior Vice President and
President, Abbott Diabetes Care, leading Abbott's global device business in
this area. Ed was Executive Vice President of TAP Pharmaceuticals, an Abbott
joint venture with Takeda Pharmaceuticals.

“We are very excited to partner with Ed again to build a specialty
pharmaceutical company focused on delivering clinically meaningful products to
patients,” said GTCR Managing Director Dean Mihas. “Ed and his team were very
successful in building Actient into a fast growing company in the space. Ed’s
industry expertise, strategic vision and operational abilities make him an
ideal partner as GTCR commits to another platform in this industry.”

“I am thrilled about the opportunity to work with GTCR again and build another
pharmaceutical company,” said Mr. Fiorentino. “GTCR was an ideal partner
during Actient’s formation, growth period and recent sale to Auxilium. The
firm has a long history of backing experienced managers and providing them
with the resources and support required to build successful companies through
both organic growth and acquisitions. Crealta is GTCR’s sixth pharmaceutical
platform and is well positioned to benefit from the firm’s deep domain
knowledge and track record.”

“GTCR’s commitment to Ed and the formation of Crealta is a reflection of our
outlook for investing capital in the pharmaceutical industry,” added Ben
Daverman, Vice President at GTCR. “We are actively looking for acquisitions
and we believe there will continue to be a number of compelling investment
opportunities in the market. Working with Ed, we are in a unique position to
evaluate and pursue select assets.”

GTCR’s investment in Crealta will be made from GTCR Fund X LP, a private
equity fund with $3.25 billion of committed capital.

About GTCR

Founded in 1980, GTCR is a leading private equity firm focused on investing in
growth companies in the Financial Services & Technology, Healthcare and
Information Services & Technology industries. The Chicago-based firm pioneered
The Leaders Strategy™ – finding and partnering with management leaders in core
domains to identify, acquire and build market-leading companies through
transformational acquisitions and organic growth. Since its inception, GTCR
has invested more than $10 billion in over 200 companies. For more
information, please visit www.gtcr.com.

About Crealta Pharmaceuticals

Crealta Pharmaceuticals is a specialty pharmaceutical company focused on
therapeutics to improve patient outcomes. The company was formed to acquire
specialty pharmaceutical companies and products with a focus on select
physician specialties. For more information about Crealta Pharmaceuticals,
please contact (312) 933-4903.

Contact:

For GTCR
Kellie Kennedy, 312-933-4903
 
Press spacebar to pause and continue. Press esc to stop.